Bristol-Myers Squibb Co. said a combination of its cancer treatments Opdivo and Yervoy in a first-line setting was better at containing the spread of tumor in patients with non-small cell lung cancer when compared to chemotherapy.
The combination met its co-primary endpoint of progression-free survival in an ongoing phase 3 study known as CheckMate -227.
The trial's data monitoring committee has recommended that the study continue based on an interim analysis of the number of patients whose tumors shrank.
More recently, the company said the combination showed durable clinical benefit in colon cancer patients enrolled in a phase 2 study.
